drugset
drugset / Trial / NCT04630808

MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT04630808 ↗

Phase 3 Completed 696 enrolled Nicox Ophthalmics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma. Subjects will be randomized in a 1:1 ratio to NCX 470 0.1% or to latanoprost 0.005% to be administered to both eyes once daily in the evening for up to 12 months.

Timeline

Start
2020-11-09
Primary completion
2025-04-11
Completion
2025-06-25

Drugs

EvaluationDrugModalityDoseRoute
Comparator Latanoprost Small molecule 0.005 % —
Subject NCX 470 Unknown 0.1 % —

Indications

ocular hypertension open-angle glaucoma